Clin2
NCT07066917Likely a fitRecruiting

Breast cancer treatment response study

Metastatic Breast Cancer

Part of Cancer, Skin clinical trials.

This study looks at how well newer treatments work for advanced or metastatic breast cancer and why some people respond better than others. It is for anyone with HR-positive, HER2-positive/low, or triple-negative breast cancer who has started at least one treatment cycle.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
150 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older
  • You have been diagnosed with advanced or metastatic breast cancer (stage 4 or spread beyond the breast)
  • Your cancer is hormone receptor positive (HR+), or HER2 positive/low, or triple negative (TNBC)
  • You have received at least one full cycle of treatment for this cancer
  • You are willing to provide tissue or blood samples and let researchers look at your medical records

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07593196Not yet recruiting
HER2-Positive Metastatic Breast Cancer Treatment Study

This study looks at how patients with advanced breast cancer (HER2-positive type) respond to anti-HER2 drugs over time. Researchers in Kazakhstan are reviewing medical records to understand which treatments work best and help improve care for future patients.

Oral, Kazakhstan
NCT07073755Recruiting
Study of next treatments after targeted therapy resistance for advanced breast cancer

This study looks at what happens when people with advanced breast cancer switch to a new treatment after their cancer becomes resistant to targeted therapies like CDK4/6 inhibitors, PIK3CA inhibitors, or T-DXd. Researchers want to understand which next treatments work best in real life.

Changsha, Hunan
NCT04660435Recruiting
Study how breast cancers resist CDK4/6 inhibitor treatment

This study looks at why some ER-positive, HER2-negative metastatic breast cancers don’t respond well to CDK4/6 inhibitors combined with hormone therapy. It may help researchers understand resistance and improve future treatment choices for people like you.

Prato, Tuscany
NCT02102165Recruiting
Study samples from metastatic triple-negative breast cancer

This study looks at tumor “clues” by using tissue and blood samples in people with metastatic breast cancer (with specific subtype). It aims to better understand what drives the cancer, which may help guide future treatments.

Brussels
NCT07233928Recruiting
Breast cancer protein study in different subtypes

This trial takes a close look at the proteins inside breast cancer cells, using samples from people with different subtypes. It aims to better understand how each type behaves, which could help guide future treatments.

Toulouse
NCT02819882Recruiting
Registry study for advanced or metastatic breast cancer

This study collects health and treatment information from people with breast cancer that cannot be fully removed by surgery or that has spread to other parts of the body. It may help researchers better understand which treatments are used and how people do over time.

Elche, Alicante

Hear when a new Metastatic Breast Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.